Vyant Bio, Inc. (VYNT)
|52 Week Range||0.8789-9.85|
|1y Target Est||-|
|DCF Unlevered||VYNT DCF ->|
|DCF Levered||VYNT LDCF ->|
|Debt / Equity||66.47%||Buy|
Upgrades & Downgrades
Latest VYNT news
Vyant Bio, Inc. (VYNT) Q3 2022 Earnings Call Transcript
17 November 2022
Vyant Bio, Inc. (NASDAQ:VYNT ) Q3 2022 Earnings Conference Call November 16, 2022 4:30 PM ET Company Participants Jay Roberts - Chief Executive Officer Andy LaFrence - Chief Financial Officer Dr. Robe...
Vyant Bio in position to be fully funded through 2023 following sale of subsidiary, 3Q results show
15 November 2022
Vyant Bio (NASDAQ:VYNT) Inc has reported its third-quarter financial results and announced it expects to be able to fund operations through to at least the end of 2023. The company had $9.4 million of...
Vyant Bio showcases 'promise and potential' of its drug discovery platform at Boston medical confere...
11 November 2022
Vyant Bio (NASDAQ:VYNT) Inc senior scientist Matthew Green delivered poster presentations this week at the Loulou Foundation's CDKL5 forum held in Boston. CDKL5 (cyclin-dependent kinase-like 5) defic...
Vyant Bio sells biotech branch vivoPharm to Reaction Biology for $5.5 million
3 November 2022
Vyant Bio (NASDAQ:VYNT) Inc said it has closed a definitive agreement with Reaction Biology Corporation in the sale of its subsidiary vivoPharm LLC, allowing Reaction to expand its suite of drug disco...
Vyant Bio to Present at the LD Micro Main Event XV on Wednesday, October 26, 2022
24 October 2022
- To Discuss its Novel Drug Discovery Platform that i s A ccelerat ing the P rocess of F inding C ures for N eurogenerative D iseases
Vyant Bio to Present at the H.C. Wainwright 24th Annual Global Investment Conference
31 August 2022
CHERRY HILL, N.J., Aug. 31, 2022 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (“Vyant Bio” or “Company”) (Nasdaq: VYNT) is an innovative biotechnology company reinventing drug discovery for complex neurodevelo...
Vyant Bio posts Q2 results, set to advance VYNT-0126 to treat Rett Syndrome into clinical trials ear...
23 August 2022
Vyant Bio (NASDAQ:VYNT) Inc revealed that it is advancing its repurposed drug candidate, VYNT-0126 to treat Rett Syndrome, into clinical trials early next year based on pre-clinical efficacy data and ...
Vyant Bio, Inc. (VYNT) CEO Jay Roberts on Q2 2022 Results - Earnings Call Transcript
22 August 2022
Vyant Bio, Inc. (NASDAQ:VYNT ) Q2 2022 Results Earnings Conference Call August 22, 2022 4:30 PM ET Company Participants Jay Roberts - President and Chief Executive Officer Andrew LaFrence - Chief Fina...
Vyant Bio Announces Rescheduled Investor Conference Call and Webcast for the Second Quarter and Firs...
19 August 2022
CHERRY HILL, N.J., Aug. 19, 2022 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (“Vyant Bio” or “Company”) (Nasdaq: VYNT) is an innovative biotechnology company reinventing drug discovery for complex neurodevelo...